Clinical Trials
16 trialsNCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT04099888 2023-09-11
RELEASE
PCI Biotech AS
Phase 2 Terminated
NCT05266430 2023-08-09
IL
Aura Biosciences
Terminated
NCT01468623 2023-07-19
PROFUSE
Myriad Genetic Laboratories, Inc.
Phase 4 Terminated
NCT03393000 2021-07-22
INTACT
Diffusion Pharmaceuticals Inc
Phase 3 Terminated
NCT02448810 2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
Phase 2 Terminated
NCT03301597 2021-03-30
LAUNCH
Nohla Therapeutics, Inc.
Phase 2 Terminated
NCT03202446 2018-02-23
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Eske Corporation S.A.C
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01353222 2017-05-25
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
Phase 2 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT00412217 2016-11-25
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT00977379 2016-11-15
XERAD
Hoffmann-La Roche
Phase 2 Terminated
NCT01558687 2014-02-04
Cilengitide Imaging Trial in Glioblastoma
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT00574860 2013-09-20
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
Endo Pharmaceuticals
Phase 3 Terminated